NCT06231953 A Prospective, Multi-center Clinical Study to Establish Multi-Cancer Early Detection Platform Through the Analysis of Whole Genome Sequencing of Circulating DNA in Cancer Patients and Healthy Volunteers
| NCT ID | NCT06231953 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yonsei University |
| Condition | Invasive Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,000 participants |
| Start Date | 2022-10-13 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,000 participants in total. It began in 2022-10-13 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, multi-center clinical study of Multi-Cancer Early Detection (MCED) testing in cancer patients and healthy volunteers. The purpose of this study is to establish MCED platform through the analysis of whole genome sequencing of circulating DNA. The study will enroll 4,000 subjects as defined by eligibility criteria at up to 10 clinical institutions in South Korea.
Eligibility Criteria
Inclusion Criteria: * Aged 19 years or older * Subjects who have been diagnosed with stages 1 to 4 of solid tumor or healthy volunteers who have scheduled a cancer screening examination * Subjects who have agreed to provide clinical information and blood samples * Subjects who have agreed for the storage and secondary use of residual blood samples for research * Subjects who have understood the study and are able to provide a written informed consent Exclusion Criteria: * Subjects who are not appropriate for the study because of intellectual disabilities or severe mental disorders * Subjects with a history of HIV, HTLV, or Syphilis infection * Subjects with primary site unknown cancer or synchronous or metachronous double primary cancers * Subjects who have diagnosed with any other malignant tumor within the past 5 years (except for cured non-melanoma skin cancer, in situ cancer, or thyroid cancer)
Contact & Investigator
Joohyuk Sohn
PRINCIPAL INVESTIGATOR
Division of Medical Oncology, Yonsei Cancer Center, Yonsei Univ. College of Medicine
Frequently Asked Questions
Who can join the NCT06231953 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Invasive Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06231953 currently recruiting?
Yes, NCT06231953 is actively recruiting participants. Contact the research team at oncosohn@yuhs.ac for enrollment information.
Where is the NCT06231953 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06231953 clinical trial?
NCT06231953 is sponsored by Yonsei University. The principal investigator is Joohyuk Sohn at Division of Medical Oncology, Yonsei Cancer Center, Yonsei Univ. College of Medicine. The trial plans to enroll 4,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.